High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era

Armitage, 1998, New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histological subtypes Non-Hodgkin's Lymphoma Classification Project, J. Clin. Oncol., 16, 2780, 10.1200/JCO.1998.16.8.2780 A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood (1997); 89 3909-18. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, N Engl J Med, 329 (1993) 987–994. Sehn, 2007, The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP, Blood, 109, 1857, 10.1182/blood-2006-08-038257 Ziepert, 2010, Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era, J. Clin. Oncol., 28, 2373, 10.1200/JCO.2009.26.2493 Zhou, 2014, An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era, Blood, 123, 837, 10.1182/blood-2013-09-524108 Chung, 2007, Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index, Blood, 110, 1278, 10.1182/blood-2007-01-070300 Hodges, 1994, Bone marrow involvement in large-cell lymphoma: prognostic implications of discordant disease, Am. J. Clin. Pathol., 101, 305, 10.1093/ajcp/101.3.305 Sehn, 2011, Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP, J. Clin. Oncol., 29, 1452, 10.1200/JCO.2010.33.3419 Campbell, 2006, The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement, Eur. J. Haematol., 76, 473, 10.1111/j.1600-0609.2006.00644.x Song, 2012, Clinical significance of metabolic tumor volume by PET/CT in stage II and III of diffuse large B cell lymphoma without extranodal site involvement, Ann. Hematol., 91, 697, 10.1007/s00277-011-1357-2 Song, 2013, Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma, Leukemia Res., 37, 58, 10.1016/j.leukres.2012.09.011 Song, 2012, Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma, Cancer Sci., 103, 477, 10.1111/j.1349-7006.2011.02164.x Meignan, 2014, Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients, Eur. J. Nucl. Med. Mol. Imaging, 41, 1113, 10.1007/s00259-014-2705-y Boellaard, 2010, FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0, Eur. J. Nucl. Med. Mol. Imaging, 37, 181, 10.1007/s00259-009-1297-4 Freudenberg, 2004, FDG-PET/CT in re-staging of patients with lymphoma, Eur. J. Nucl. Med. Mol. Imaging, 31, 325, 10.1007/s00259-003-1375-y Cheson, 2007, Revised response criteria for malignant lymphoma, J. Clin. Oncol., 25, 579, 10.1200/JCO.2006.09.2403 Allen-Auerbach, 2004, Comparison between 2-deoxy-2-[18F] fluoro-d-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma, Mol. Imaging Biol, 6, 411, 10.1016/j.mibio.2004.08.004 Song, 2013, Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma, Cancer Sci., 104, 1656, 10.1111/cas.12282 Kim, 2013, Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement, J. Hematol. Oncol., 6, 76, 10.1186/1756-8722-6-76